Cencora

(New York Stock Exchange)
Back to all articles
Very Bullish +85

Cencora stock enters fiscal 2027 with stronger earnings outlook

Dividend Earnings report AI-generated analysis

πŸ“ˆ Cencora reported fourth-quarter revenue of $88.4 billion, a 5.5% increase year over year.

πŸ’° Adjusted diluted earnings per share surged 21.4% to $4.66 in the latest quarter.

πŸš€ Management raised the quarterly dividend to $0.66 per share for fiscal 2027.

πŸ“… Fiscal 2027 adjusted diluted EPS guidance is set between $19.40 and $19.75.

πŸ” Specialty services segment is projected to grow revenue by 9% to 14% in the upcoming fiscal year.

🀝 The MWI Animal Health merger with Covetrus is expected to close on March 31, 2027.

πŸ’Ή Adjusted operating income increased 22.1% to $1.2 billion for the quarter ended September 30.

πŸ“Š Adjusted gross profit rose 23.0% to $3.6 billion, expanding margins to 1.41%.

πŸ—οΈ The company is restructuring its reporting to prioritize Pharmaceutical Distribution and Services alongside Specialty Pharmaceutical and Provider Services.

πŸ“‰ GAAP diluted earnings per share reached $2.71, a turnaround from a loss of $1.75 in the prior-year quarter.

Bullish Signals
  • Cencora reported strong fourth-quarter revenue growth of 5.5% year-over-year, reaching $88.4 billion.
  • Adjusted diluted earnings per share increased significantly by 21.4% to $4.66 in the latest quarter.
  • The company raised its quarterly dividend to $0.66 per share, demonstrating confidence in capital allocation.
  • Management forecasts fiscal 2027 adjusted diluted EPS growth of 8% to 10%, targeting $19.40 to $19.75 per share.
  • The specialty services segment is expected to deliver superior revenue growth of 9% to 14% compared to the distribution business.
  • Adjusted operating income expanded by 22.1% to $1.2 billion, highlighting improved operational efficiency.
  • The adjusted gross profit rose 23.0% to $3.6 billion, contributing to an expanded operating margin of 1.41%.
  • The upcoming MWI Animal Health merger with Covetrus is expected to close by March 31, 2027, adding to the specialty portfolio.
Full Analysis
Cencora Inc. reported robust fourth-quarter financial results, with revenue rising 5.5% year-over-year to $88.4 billion and adjusted diluted earnings per share increasing 21.4% to $4.66. The company also declared a quarterly dividend increase to $0.66 per share, signaling confidence in its cash flow generation capabilities for fiscal 2027. Management has outlined a revised operating framework that places specialty services at the center of its growth strategy. For fiscal 2027, Cencora projects revenue growth between 3% and 5%, with adjusted diluted earnings per share expected to reach $19.40 to $19.75, representing an 8% to 10% increase from the prior year. The company anticipates that its specialty services segment will outperform its distribution business, forecasting revenue growth of 9% to 14% and operating income growth of 18% to 21%. This outlook assumes the successful closing of the MWI Animal Health merger with Covetrus by March 31, 2027, which is expected to further bolster its specialty portfolio. Adjusted operating income expanded significantly by 22.1% to $1.2 billion, while adjusted gross profit rose 23.0% to $3.6 billion. The adjusted operating margin improved to 1.41%, reflecting strong operational efficiency and the successful integration of recent acquisitions into the broader business model.